> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Public Meeting on Drug Benefit-Risk Assessment Approaches
- URL: https://www.fdaweb.com/public-meeting-on-drug-benefit-risk-assessment-approaches/
- Published: 2019-04-23T12:00:00.000Z
- Updated: 2026-09-15T01:21:55.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143928

*Federal Register* notice: FDA has announced a 5/16 public meeting entitled “Characterizing FDA’s Approach to Benefit-Risk Assessment Throughout the Medical Product Life Cycle.” The meeting is intended to gather stakeholder input on applying FDA’s Benefit-Risk Framework throughout the human drug lifecycle and best approaches to communicating FDA’s benefit-risk assessment. The input will support development of a draft guidance on benefit-risk assessment for new drugs and biologics and result in a publicly available summary report from Duke-Margolis. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-08219.pdf?ref=fdaweb.com).